Alternative Name: Testosterone undecanoate (TU) + etonogestrel (ENG)

Description: The tested product was a combination of an etonogestrel (ENG) implant combined with testosterone undecanoate (TU) injections for male contraception.

Product Details

User: Male

Hormonal: Yes

Delivery Method: Injectable, Subdermal

Duration Type: Short-acting

Active Pharmaceutical Ingredient (API):
  • testosterone undecanoate
  • etonogestrel

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Organon

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase II

Active Development: No

Status Details:
  • A Phase IIb, placebo-controlled trial investigating the efficacy, safety and pharmacokinetics of the product was completed in 2006.

Additional Information

  • Mommers E, et al. (2008) Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 93(7): 2572-80.

  • Liu PY, McLachlan RI. (2008) Male hormonal contraception: so near and yet so far. J Clin Endocrinol Metab. 93(7): 2474-6.

  • In 2007, Schering-Plough Corporation acquired Organon and in 2009, merged with Merck & Co.

Vertical Tabs